Close
U S G r a n t s . c o m
August 31, 2025, 8:54 am UTC

Pulmonara Labs Inc 86-2053646 | Government Grant Application

Pulmonara Labs Inc | Application Preview

 

Pulmonara Labs Inc. is seeking government grants to support its respiratory drug product development, which involves several stages of clinical trials and regulatory review. The estimated costs for each phase are significant, with R&D at approximately $2 million, phase 1 at $5.2 million, phase 2 at $12.3 million, phase 3 at $23.6 million, FDA review at $2 million, and phase 4 at $72.3 million.

The company plans to scale operations through a partnership with a Pennsylvania university, which will help navigate the clinical trial process. The need for funding is underscored by the company's focus on developing a product that addresses shortages in respiratory medications, particularly in light of ongoing global health challenges such as the COVID-19 pandemic.

In terms of competition, Pulmonara Labs faces established companies like Teva Pharma and Tetra Biopharma. However, Pulmonara believes it has a competitive edge due to its focus on specific pathologies that its competitors are not addressing, positioning the company uniquely in the market.

  • General Information

    Business Registration Number: 86-2053646

    Location: Philadelphia, PA, United States

    Length of Operation: 0.5

    Number of Employees:

    Annual Gross Income:

    Annual Gross Expense:

    Open to Loans: YES

  • Funding Usage

    Expenses will vary overtime as product moves through clinical trial pipeline. Per average cost of respiratory drug product development, R&D stage costs approx $2M, phase 1 - $5.2M , phase 2 - $12.3M , phase 3 - $23.6M , FDA Review - $2M and phase 4 - $72.3M

  • Business Plan

    Business will scale up as it moves through clinical trial pipeline with the assistance of a collaborative partnership with a Pennsylvania University The implication for the product being developed has a strong relationship with the ever changing global respiratory pandemic. This product looks to address the massive shortages of respiratory drug products while also potentially serving as a means to treat COVID-19

  • Self Identified Competition

    Teva Pharma, Tetra Biopharma While competitors are looking at using similar active ingredients to address illnesses. These organizations do not have the current pathologies we at Pulmonara are looking to address

  • Contact Applicant

    Subscribe to our Administrator Dashboard to gain full access to this application. Learn More

 

USGrants.org applicant portal membership